Innovent Biologics Ownership
IVBXF Stock | USD 4.85 0.24 4.72% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Innovent |
Innovent Pink Sheet Ownership Analysis
About 44.0% of the company shares are owned by institutional investors. The book value of Innovent Biologics was currently reported as 6.54. The company recorded a loss per share of 0.32. Innovent Biologics had not issued any dividends in recent years. Innovent Biologics, Inc. operates as a biopharmaceutical company in China. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the Peoples Republic of China. Innovent Biologics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 5538 people.The quote for Innovent Biologics is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To learn more about Innovent Biologics call the company at 86 512 6956 6088 or check out https://www.innoventbio.com.Currently Active Assets on Macroaxis
Other Information on Investing in Innovent Pink Sheet
Innovent Biologics financial ratios help investors to determine whether Innovent Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Innovent with respect to the benefits of owning Innovent Biologics security.